Similarly, Lee et al. [134] applied this approach to gauge the signalling shifts involved in the development of resistance against an EGFR/HER2 inhibitor (lapatinib) in human gastric cancer cells (SNU216 cells). The gene discussed is ERBB2; the disease is gastric cancer.